CHA₂DS₂-VASc-Score räknare: Stroke-risk vid förmaksflimmer

Räknare

Bedömning

Rekommendation för OAK ESC 20201

  • Män:
    • CHA₂DS₂-VASc-Score ≥ 2: OAK rekommenderas (ESC IA)
    • CHA₂DS₂-VASc-Score =1 “should be considered” (ESC IIA), “considering individual characteristics and patient preferences”
  • Kvinnor:
    • CHA₂DS₂-VASc-Score ≥ 3: OAK rekommenderas (ESC IA)
    • CHA₂DS₂-VASc-Score =2 “should be considered” (ESC IIA), “considering individual characteristics and patient preferences”

CHA₂DS₂-VASc-Score: Förklaring av riskfaktorer

CHA₂DS₂-VASc-Score2 ska användas (ESC IA indikation) för bedömning av stroke-risken och vid beslutsfattning om oral antikoagulation (OAK) hos patienter med förmaksflimmer.3

RiskfaktorPoäng
CCongestive heart failure
Signs/symptoms of heart failure or objective evidence of reduced left ventricular ejection fraction		1
HHypertension
Resting blood pressure >140/90 mmHg on at least two occasions or current antihypertensive treatment		1
A₂Age 75 years or older2
DDiabetes mellitus
Fasting glucose >7 mmol/L or treatment with oral hypoglycaemic agent and/or insulin		1
S₂Previous stroke, transient ischaemic attack, or thromboembolism2
VVascular disease
Previous myocardial infarction, peripheral artery disease, or aortic plaque		1
AAge 65–74 years1
ScSex category (female)1

ESC-tabell: detaljerat om riskfaktorer

ESC 2020: Tabell med detaljförklaring av varje riskfaktor: (klicka på dropdown)
förklaring av CHA₂DS₂-VASc-Score (ESC 2020)
table 8 in ESC guideline förmaksflimmer 2020

Hur CHA₂DS₂-VASc-Score ska användas

praktisk använding av chads-vasc score i beslutfattning om antikoagulation för förmaksflimmer
fig 12 in ESC guideline förmaksflimmer 2020

Relaterad sida

Förmaksflimmer

Litteratur

ESC guideline förmaksflimmer 20201

ESC guidline förmaksflimmer 2016

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation2 (CHA₂DS₂-VASc-Score publikation)

Last Updated on July 4, 2024 by Christian Dworeck

Christian Dworeck
Latest posts by Christian Dworeck (see all)
  1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Erratum in: Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Feb 1;42(5):541-543. PMID: 32860505. [↩] [↩]
  2. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17. PMID: 19762550. [↩] [↩]
  3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210 [↩]

Leave a Reply